Study Questions Value of Interim PET Imaging to Guide Frontline Hodgkin Treatment
HOUSTON — Interim PET-CT imaging (PET2) had almost no impact on clinical decision-making for Hodgkin lymphoma treated with brentuximab vedotin (Adcetris), according to a small clinical study reported here. One of 40 patients had a change in treatment based on PET2 results, regardless of whether the scans were positive or negative. Outcomes did not differ […]